全國職稱英語考試 衛(wèi)生類B級 閱讀與完形填空押題【孫、王、李三個王牌老師綜合而來】

1、once daily pill could simplify hiv treatmentbeistol-myers squibb and gilead sciences have combined many hiv drugs into a single pill. sometimes the best medicine is moer than one kind of medicine. maiaria,tuberculosis and hiv/aids, for example, are all treated with combinations of drugs. but that ca

2、n mean a lot of pills to take. it would be simpler if deug companies combined all the medicines into a single pill, taken just once a day .now, two companies say they have done that foe people just starting treatment for hiv, the virus that causes aids. the companies are bristol-myers squibb and gil

3、ead sciences. they have developed a single pill that combines three drugs currently on the market . bristol-myers squibb sells one of them under the name of sustiva. gilead combined the others, emtriva and viread, into a single pill in two thousand four.combining drugs involeves more than technical

4、issues. it also involves issues of competition if the drugs are made by different companies. the new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of hiv. in january the new england journal of medicine published a study of the ne

5、w pill . researchers compared its effectiveness to that of the widely used combination of sustiva and combivir. combivir contains two drugs, azt and 3tc. the researchers say that after one year of treatment, the new pill suppressed hiv levels in more patients and with fewer side effects. gilead paid

6、 for the study. professor joel gallant at the johns hopkins school of medicine in baltimore, maryland, led the reaearch . he is paid adviser to gilead ang bristol-meyers squibb as well as the maker of combivir, glaxo smith kline. glaxo smith kline reacted to the findings by saying that a single stud

7、y is of limited value. it says the effectiveness of combivir has been shown in each of more the fifty studies.the price of the new once-daily pill has not beet announced. but gilead ang bristol-myers squibb say they will provide it at reduced cost to developing countries. they plan in the next few m

8、onths to ask the united states food and drug administration to approve the new pill. there are limits to who could take it because of the different drugs it contains.for example pregnant women are told not to take sustiva because of the risk of birth disorders.experts say more than forty million peo

9、ple around the world are living with hiv.once daily pill could simplify hiv treatmentbeistol-myers squibb and gilead sciences have combined many hiv drugs into a single pill. sometimes the best medicine is moer than one kind of medicine. maiaria,tuberculosis and hiv/aids, for example, are all treate

10、d with combinations of drugs. but that can mean a lot of pills to take. it would be simpler if deug companies combined all the medicines into a single pill, taken just once a day .now, two companies say they have done that foe people just starting treatment for hiv, the virus that causes aids. the c

11、ompanies are bristol-myers squibb and gilead sciences. they have developed a single pill that combines three drugs currently on the market . bristol-myers squibb sells one of them under the name of sustiva. gilead combined the others, emtriva and viread, into a single pill in two thousand four.combi

12、ning drugs involeves more than technical issues. it also involves issues of competition if the drugs are made by different companies. the new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of hiv. in january the new england journa

13、l of medicine published a study of the new pill . researchers compared its effectiveness to that of the widely used combination of sustiva and combivir. combivir contains two drugs, azt and 3tc. the researchers say that after one year of treatment, the new pill suppressed hiv levels in more patients

14、 and with fewer side effects. gilead paid for the study. professor joel gallant at the johns hopkins school of medicine in baltimore, maryland, led the reaearch . he is paid adviser to gilead ang bristol-meyers squibb as well as the maker of combivir, glaxo smith kline. glaxo smith kline reacted to

15、the findings by saying that a single study is of limited value. it says the effectiveness of combivir has been shown in each of more the fifty studies.the price of the new once-daily pill has not beet announced. but gilead ang bristol-myers squibb say they will provide it at reduced cost to developi

16、ng countries. they plan in the next few months to ask the united states food and drug administration to approve the new pill. there are limits to who could take it because of the different drugs it contains.for example pregnant women are told not to take sustiva because of the risk of birth disorder

17、s.experts say more than forty million people around the world are living with hiv.once daily pill could simplify hiv treatmentbeistol-myers squibb and gilead sciences have combined many hiv drugs into a single pill. sometimes the best medicine is moer than one kind of medicine. maiaria,tuberculosis

18、and hiv/aids, for example, are all treated with combinations of drugs. but that can mean a lot of pills to take. it would be simpler if deug companies combined all the medicines into a single pill, taken just once a day .now, two companies say they have done that foe people just starting treatment f

19、or hiv, the virus that causes aids. the companies are bristol-myers squibb and gilead sciences. they have developed a single pill that combines three drugs currently on the market . bristol-myers squibb sells one of them under the name of sustiva. gilead combined the others, emtriva and viread, into

20、 a single pill in two thousand four.combining drugs involeves more than technical issues. it also involves issues of competition if the drugs are made by different companies. the new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment

21、of hiv. in january the new england journal of medicine published a study of the new pill . researchers compared its effectiveness to that of the widely used combination of sustiva and combivir. combivir contains two drugs, azt and 3tc. the researchers say that after one year of treatment, the new pi

22、ll suppressed hiv levels in more patients and with fewer side effects. gilead paid for the study. professor joel gallant at the johns hopkins school of medicine in baltimore, maryland, led the reaearch . he is paid adviser to gilead ang bristol-meyers squibb as well as the maker of combivir, glaxo s

23、mith kline. glaxo smith kline reacted to the findings by saying that a single study is of limited value. it says the effectiveness of combivir has been shown in each of more the fifty studies.the price of the new once-daily pill has not beet announced. but gilead ang bristol-myers squibb say they wi

24、ll provide it at reduced cost to developing countries. they plan in the next few months to ask the united states food and drug administration to approve the new pill. there are limits to who could take it because of the different drugs it contains.for example pregnant women are told not to take sust

25、iva because of the risk of birth disorders.experts say more than forty million people around the world are living with hiv.once daily pill could simplify hiv treatmentbeistol-myers squibb and gilead sciences have combined many hiv drugs into a single pill. sometimes the best medicine is moer than on

26、e kind of medicine. maiaria,tuberculosis and hiv/aids, for example, are all treated with combinations of drugs. but that can mean a lot of pills to take. it would be simpler if deug companies combined all the medicines into a single pill, taken just once a day .now, two companies say they have done

27、that foe people just starting treatment for hiv, the virus that causes aids. the companies are bristol-myers squibb and gilead sciences. they have developed a single pill that combines three drugs currently on the market . bristol-myers squibb sells one of them under the name of sustiva. gilead comb

28、ined the others, emtriva and viread, into a single pill in two thousand four.combining drugs involeves more than technical issues. it also involves issues of competition if the drugs are made by different companies. the new once-daily pill is the result of what is described as the first joint ventur

29、e agreement of its kind in the treatment of hiv. in january the new england journal of medicine published a study of the new pill . researchers compared its effectiveness to that of the widely used combination of sustiva and combivir. combivir contains two drugs, azt and 3tc. the researchers say tha

30、t after one year of treatment, the new pill suppressed hiv levels in more patients and with fewer side effects. gilead paid for the study. professor joel gallant at the johns hopkins school of medicine in baltimore, maryland, led the reaearch . he is paid adviser to gilead ang bristol-meyers squibb

31、as well as the maker of combivir, glaxo smith kline. glaxo smith kline reacted to the findings by saying that a single study is of limited value. it says the effectiveness of combivir has been shown in each of more the fifty studies.the price of the new once-daily pill has not beet announced. but gi

32、lead ang bristol-myers squibb say they will provide it at reduced cost to developing countries. they plan in the next few months to ask the united states food and drug administration to approve the new pill. there are limits to who could take it because of the different drugs it contains.for example

33、 pregnant women are told not to take sustiva because of the risk of birth disorders.experts say more than forty million people around the world are living with hiv.the case of the disappearing fingerprints one useful anti-cancer drug can effectively erase the whorls and other characteristic marks th

34、at give people their distinctive fingerprints.losing them could become troublesome.a case released online in a letter by annals of oncology indicates how big a problem of losing. eng-huat tan,a singapore-based medical doctor describes a 62-year old man who has used capecitabine to treat his nasophar

35、yngeal cancer.after three years on the drug,the patient decided to visit u.s. relatives last decembr.but he was stopped by u.s. customs officials for 4 hours after entering the country when those officials couldnt get fingerprints from the man.there were no distinctive swirly marks appearing from hi

36、s index finger. u.s.customs has been fingerprinting incoming foreign visitors for years,tan says.theri index fingers are printed and screened against digital files of the fingerprints of bad guys-terrorists and potential criminals that our federal guardians have been tasked with keeping out of the c

37、ountry,unfortunately,for the singaporean traveler,one potential side effedc of his drug treatment is a smoothing of the tissue on the finger pads.hence,no fingerprints. “it is uncertain when fingerprint loss will begin to take place in patients who are taking capecitabine,” tan points out. so he cau

38、tions any physicians who prescribe the drug to provide their patients with a doctors note pointing out that their medicine may cause fingerprints to disappear. eventually,the singapore traveler made it into the united states. i guess the name on his passport didnt raise any red flags.but hes also no

39、w got the explanatory doctors note-and wont leave home without it. by the way,maybe the food and drug administration,which approved use of the drug 11 years ago,should consider updating its list of side effects associated with this medicine.the current list does note that patients may experience vom

40、iting,stomach pain and some other side effects. but no where does it mention the potential for loss of fingerprints.the case of the disappearing fingerprints one useful anti-cancer drug can effectively erase the whorls and other characteristic marks that give people their distinctive fingerprints.lo

41、sing them could become troublesome.a case released online in a letter by annals of oncology indicates how big a problem of losing. eng-huat tan,a singapore-based medical doctor describes a 62-year old man who has used capecitabine to treat his nasopharyngeal cancer.after three years on the drug,the

42、patient decided to visit u.s. relatives last decembr.but he was stopped by u.s. customs officials for 4 hours after entering the country when those officials couldnt get fingerprints from the man.there were no distinctive swirly marks appearing from his index finger. u.s.customs has been fingerprint

43、ing incoming foreign visitors for years,tan says.theri index fingers are printed and screened against digital files of the fingerprints of bad guys-terrorists and potential criminals that our federal guardians have been tasked with keeping out of the country,unfortunately,for the singaporean travele

44、r,one potential side effedc of his drug treatment is a smoothing of the tissue on the finger pads.hence,no fingerprints. “it is uncertain when fingerprint loss will begin to take place in patients who are taking capecitabine,” tan points out. so he cautions any physicians who prescribe the drug to p

45、rovide their patients with a doctors note pointing out that their medicine may cause fingerprints to disappear. eventually,the singapore traveler made it into the united states. i guess the name on his passport didnt raise any red flags.but hes also now got the explanatory doctors note-and wont leav

46、e home without it. by the way,maybe the food and drug administration,which approved use of the drug 11 years ago,should consider updating its list of side effects associated with this medicine.the current list does note that patients may experience vomiting,stomach pain and some other side effects.

47、but no where does it mention the potential for loss of fingerprints.the case of the disappearing fingerprints one useful anti-cancer drug can effectively erase the whorls and other characteristic marks that give people their distinctive fingerprints.losing them could become troublesome.a case releas

48、ed online in a letter by annals of oncology indicates how big a problem of losing. eng-huat tan,a singapore-based medical doctor describes a 62-year old man who has used capecitabine to treat his nasopharyngeal cancer.after three years on the drug,the patient decided to visit u.s. relatives last dec

49、embr.but he was stopped by u.s. customs officials for 4 hours after entering the country when those officials couldnt get fingerprints from the man.there were no distinctive swirly marks appearing from his index finger. u.s.customs has been fingerprinting incoming foreign visitors for years,tan says

50、.theri index fingers are printed and screened against digital files of the fingerprints of bad guys-terrorists and potential criminals that our federal guardians have been tasked with keeping out of the country,unfortunately,for the singaporean traveler,one potential side effedc of his drug treatmen

51、t is a smoothing of the tissue on the finger pads.hence,no fingerprints. “it is uncertain when fingerprint loss will begin to take place in patients who are taking capecitabine,” tan points out. so he cautions any physicians who prescribe the drug to provide their patients with a doctors note pointi

52、ng out that their medicine may cause fingerprints to disappear. eventually,the singapore traveler made it into the united states. i guess the name on his passport didnt raise any red flags.but hes also now got the explanatory doctors note-and wont leave home without it. by the way,maybe the food and

53、 drug administration,which approved use of the drug 11 years ago,should consider updating its list of side effects associated with this medicine.the current list does note that patients may experience vomiting,stomach pain and some other side effects. but no where does it mention the potential for l

54、oss of fingerprints.the case of the disappearing fingerprints one useful anti-cancer drug can effectively erase the whorls and other characteristic marks that give people their distinctive fingerprints.losing them could become troublesome.a case released online in a letter by annals of oncology indi

55、cates how big a problem of losing. eng-huat tan,a singapore-based medical doctor describes a 62-year old man who has used capecitabine to treat his nasopharyngeal cancer.after three years on the drug,the patient decided to visit u.s. relatives last decembr.but he was stopped by u.s. customs official

56、s for 4 hours after entering the country when those officials couldnt get fingerprints from the man.there were no distinctive swirly marks appearing from his index finger. u.s.customs has been fingerprinting incoming foreign visitors for years,tan says.theri index fingers are printed and screened ag

57、ainst digital files of the fingerprints of bad guys-terrorists and potential criminals that our federal guardians have been tasked with keeping out of the country,unfortunately,for the singaporean traveler,one potential side effedc of his drug treatment is a smoothing of the tissue on the finger pad

58、s.hence,no fingerprints. “it is uncertain when fingerprint loss will begin to take place in patients who are taking capecitabine,” tan points out. so he cautions any physicians who prescribe the drug to provide their patients with a doctors note pointing out that their medicine may cause fingerprint

59、s to disappear. eventually,the singapore traveler made it into the united states. i guess the name on his passport didnt raise any red flags.but hes also now got the explanatory doctors note-and wont leave home without it. by the way,maybe the food and drug administration,which approved use of the drug 11 years ago,should consider updating its list of side ef